Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 1, 2012, Pages 446-457

  Kjellsson, Maria C ^a,b   Via, Laura E ^c   Goh, Anne ^d   Weiner, Danielle ^c   Low, Kang Min ^d   Kern, Steven ^a   Pillai, Goonaseelan ^a   Barry III, Clifton E ^c   Dartois, Véronique ^d  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UPPSALA UNIVERSITY   (Sweden)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d NOVARTIS INSTITUTE FOR TROPICAL DISEASES   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PENETRATION; DRUG TISSUE LEVEL; FEMALE; LUNG GRANULOMA; LUNG LESION; LUNG PARENCHYMA; LUNG TUBERCULOSIS; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; STEADY STATE;

ANIMALS; ANTITUBERCULAR AGENTS; AZA COMPOUNDS; BIOLOGICAL AVAILABILITY; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRANULOMA; HUMANS; ISONIAZID; LUNG; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; QUINOLINES; RABBITS; RIFAMPIN; TISSUE EXTRACTS; TUBERCULOSIS, PULMONARY;

EID: 84455169868     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05208-11     Document Type: Article

References (62)

1. Acocella G. 1978. Clinical pharmacokinetics of rifampicin. Clin. Pharmacokinet. 3:108-127.
2. Barbour A, Scaglione F, Derendorf H. 2010. Class-dependent relevance of tissue distribution in the interpretation of anti-infective pharmacokinetic/ pharmacodynamic indices. Int. J. Antimicrob. Agents 35:431-438.
3. Barclay WR, Ebert RH, Le Roy GV, Manthei RW, Roth LJ. 1953. Distribution and excretion of radioactive isoniazid in tuberculous patients. JAMA 151:1384-1388.
4. Bareggi SR, Cerutti R, Pirola R, Riva R, Cisternino M. 1987. Clinical pharmacokinetics and metabolism of pyrazinamide in healthy volunteers. Arzneimittelforschung 37:849-854. (Pubitemid 17094393)
5. Barry CE, et al. 2009. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat. Rev. Microbiol. 7:845-855.
6. Canetti G, Parrot R, Porven G, Le Lirzin M. 1969. Rifomycin levels in the lung and tuberculous lesions in man. Acta Tuberc. Pneumol. Belg. 60: 315-322. (In French.)
7. Carceles CM, Serrano JM, Marin P, Escudero E, Fernandez-Varon E. 2006. Pharmacokinetics of moxifloxacin in rabbits after intravenous, subcutaneous and a long-acting poloxamer 407 gel formulation administration. J. Vet. Med. A Physiol. Pathol. Clin. Med. 53:300-304. (Pubitemid 44114749)
8. Chan K, Wong CL. 1988. Pharmacokinetics of pyrazinamide in plasma and CSF of rabbits following intravenous and oral administration. Eur. J. Drug Metab. Pharmacokinet. 13:195-199. (Pubitemid 18264772)
9. Chang KC, Leung CC, Yew WW, Ho SC, Tam CM. 2004. A nested case-control study on treatment-related risk factors for early relapse of tuberculosis. Am. J. Respir. Crit. Care Med. 170:1124-1130. (Pubitemid 39488627)
10. Conte JE, Jr, Golden JA, Duncan S, McKenna E, Zurlinden E. 1999. Intrapulmonary concentrations of pyrazinamide. Antimicrob. Agents Chemother. 43:1329-1333. (Pubitemid 29259320)
11. Conte JE, Jr, et al. 2002. Effects of gender, AIDS, and acetylator status on intrapulmonary concentrations of isoniazid. Antimicrob. Agents Chemother. 46:2358-2364.
12. Dannenberg AM, Jr. 2006. Pathogenesis of human pulmonary tuberculosis. ASM Press, Washington, DC.
13. Dannenberg AM, Jr. 2006. Stages in the pathogenesis of human and rabbit tuberculosis, p 22-33. InPathogenesis of human pulmonary tuberculosis. ASM Press, Washington, DC.
14. Ellard GA, Humphries MJ, Allen BW. 1993. Cerebrospinal fluid drug concentrations and the treatment of tuberculous meningitis. Am. Rev. Respir. Dis. 148:650-655. (Pubitemid 23263774)
15. Ellard GA, Humphries MJ, Gabriel M, Teoh R. 1987. Penetration of pyrazinamide into the cerebrospinal fluid in tuberculous meningitis. Br. Med. J. (Clin. Res. ed.) 294:284-285. (Pubitemid 17006325)
16. Eum SY, et al. 2010. Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB. Chest 137: 122-128.
17. Fernandez-Varon E, et al. 2005. Pharmacokinetic-pharmacodynamic integration of moxifloxacin in rabbits after intravenous, intramuscular and oral administration. J. Vet. Pharmacol. Ther. 28:343-348. (Pubitemid 41098174)
18. Firsov AA, et al. 2000. Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses. J. Antimicrob. Chemother. 46:725-732.
19. Gobburu JV, et al. 2001. Pharmacokinetic-pharmacodynamic modeling of rivastigmine, a cholinesterase inhibitor, in patients with Alzheimer's disease. J. Clin. Pharmacol. 41:1082-1090. (Pubitemid 32880136)
20. Goutelle S, et al. 2009. Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs. Antimicrob. Agents Chemother. 53:2974-2981.
21. Gumbo T. 2010. New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. Antimicrob. Agents Chemother. 54:1484-1491.
22. Gumbo T, et al. 2004. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J. Infect. Dis. 190:1642-1651. (Pubitemid 39411014)
23. Hu Y, Coates AR, Mitchison DA. 2003. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 47:653-657. (Pubitemid 36158096)
24. Jeena PM, Bishai WR, Pasipanodya JG, Gumbo T. 2011. In silico children and the glass mouse model: clinical trial simulations to identify and individualize optimal isoniazid doses in children with tuberculosis. Antimicrob. Agents Chemother. 55:539-545.
25. Jonsson EN, Karlsson MO. 1999. Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput. Methods Programs Biomed. 58:51-64. (Pubitemid 29049052)
26. Kaplan G, et al. 2003. Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect. Immun. 71: 7099-7108. (Pubitemid 37475342)
27. Kaplan G, Tsenova L. 2011. Pulmonary tuberculosis in the rabbit, p 107-128. In Leong FJ, Dartois V, Dick T (ed), A color atlas of comparative pathology of pulmonary tuberculosis. CRC Press, Boca Raton, FL.
28. Kim DH, et al. 2008. Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 178:1075-1082.
29. Kislitsyna NA. 1985. Comparative evaluation of rifampicin and isoniazid penetration into the pathological foci of the lungs in tuberculosis patients. Probl. Tuberk., p 55-57. (In Russian.) (Pubitemid 15075388)
30. Kislitsyna NA, Kotova NI. 1980. Rifampicin and isoniazid concentration in the blood and resected lungs in tuberculosis with combined use of the preparations. Probl. Tuberk., p 63-65. (In Russian.) (Pubitemid 10061336)
31. Lee SY, Fan HW, Sutherland C, DeRyke AC, Nicolau DP. 2007. Antibacterial effects of moxifloxacin and levofloxacin simulating epithelial lining fluid concentrations against community-acquired methicillinresistant Staphylococcus aureus. Drugs R D 8:69-77. (Pubitemid 46333986)
32. Leong FJ, Eum SY, Via LE, Barry CER. 2011. Pathology of tuberculosis in the human lung, p 53-81. In Dartois V, Dick T, Leong FJ (ed), A color atlas of comparative pathology of pulmonary tuberculosis. CRC Press, Boca Raton, FL.
33. Lindbom L, Pihlgren P, Jonsson EN. 2005. PsN-toolkit-a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput. Methods Programs Biomed. 79: 241-257. (Pubitemid 41196689)
34. Lindbom L, Ribbing J, Jonsson EN. 2004. Perl-speaks-NONMEM (PsN)-a Perl module for NONMEM related programming. Comput. Methods Programs Biomed. 75:85-94. (Pubitemid 38798039)
35. Liu P, Derendorf H. 2003. Antimicrobial tissue concentrations. Infect. Dis. Clin. North Am. 17:599-613. (Pubitemid 38029155)
36. Loos U, et al. 1985. Pharmacokinetics of oral and intravenous rifampicin during chronic administration. Klin. Wochenschr. 63:1205-1211. (Pubitemid 16169743)
37. Mitchison DA. 1985. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 66:219-225. (Pubitemid 16150082)
38. Mitchison DA. 1973. Plasma concentrations of isoniazid in the treatment of tuberculosis. In Davies DS, Prichard BNC (ed), Biological effects of drugs in relation to their plasma concentrations. Macmillan, New York, NY.
39. Mitchison DA, Coates AR. 2004. Predictive in vitro models of the sterilizing activity of anti-tuberculosis drugs. Curr. Pharm. Des. 10:3285-3295. (Pubitemid 39276616)
40. Mouton JW, et al. 2008. Tissue concentrations: do we ever learn? J. Antimicrob. Chemother. 61:235-237.
41. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT. 2003. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin. Pharmacokinet. 42:819-850. (Pubitemid 36995083)
42. Noel AR, Bowker KE, Macgowan AP. 2005. Pharmacodynamics of moxifloxacin against anaerobes studied in an in vitro pharmacokinetic model. Antimicrob. Agents Chemother. 49:4234-4239. (Pubitemid 41400969)
43. O'Brien JK, Doerfler ME, Harkin TJ, Rom WN. 1998. Isoniazid levels in the bronchoalveolar lavage fluid of patients with pulmonary tuberculosis. Lung 176:205-211. (Pubitemid 28252305)
44. Pillai G, et al. 2006. Population pharmacokinetics of ibandronate in Caucasian and Japanese healthy males and postmenopausal females. Int. J. Clin. Pharmacol. Ther. 44:655-667. (Pubitemid 44896143)
45. Piotrovskii VK. 1987. The use of Weibull distribution to describe the in vivo absorption kinetics. J. Pharmacokinet. Biopharm. 15:681-686.
46. Prideaux B, et al. 2011. High-sensitivity MALDI-MRM-MS imaging of moxifloxacin distribution in tuberculosis-infected rabbit lungs and granulomatous lesions. Anal. Chem. 83:2112-2118.
47. Reed MB, et al. 2004. A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response. Nature 431:84-87. (Pubitemid 39215112)
48. Sacchettini JC, Rubin EJ, Freundlich JS. 2008. Drugs versus bugs: in pursuit of the persistent predator Mycobacterium tuberculosis. Nat. Rev. Microbiol. 6:41-52. (Pubitemid 350286219)
49. Sauermann R, et al. 2005. Antibiotic abscess penetration: fosfomycin levels measured in pus and simulated concentration-time profiles. Antimicrob. Agents Chemother. 49:4448-4454. (Pubitemid 41552572)
50. Savic RM, Jonker DM, Kerbusch T, Karlsson MO. 2007. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J. Pharmacokinet. Pharmacodyn. 34:711-726. (Pubitemid 47477040)
51. Soman A, Honeybourne D, Andrews J, Jevons G, Wise R. 1999. Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy. J. Antimicrob. Chemother. 44:835-838.
52. Stass H, Dalhoff A, Kubitza D, Schuhly U. 1998. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob. Agents Chemother. 42:2060-2065. (Pubitemid 28363093)
53. Tunblad K, et al. 2008. The use of clinical irrelevance criteria in covariate model building with application to dofetilide pharmacokinetic data. J. Pharmacokinet. Pharmacodyn. 35:503-526.
54. Via LE, et al. 2008. Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect. Immun. 76:2333-2340.
55. Wagner C, Sauermann R, Joukhadar C. 2006. Principles of antibiotic penetration into abscess fluid. Pharmacology 78:1-10. (Pubitemid 44387432)
56. Wallis RS, et al. 1999. Drug tolerance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 43:2600-2606. (Pubitemid 29519536)
57. Walubo A, Chan K, Wong CL. 1991. The pharmacokinetics of isoniazid and hydrazine metabolite in plasma and cerebrospinal fluid of rabbits. Methods Find. Exp. Clin. Pharmacol. 13:199-204.
58. Walubo A, Chan K, Woo J, Chan HS, Wong CL. 1991. The disposition of antituberculous drugs in plasma of elderly patients. II. Isoniazid, rifampicin and pyrazinamide. Methods Find. Exp. Clin. Pharmacol. 13: 551-556.
59. Wayne LG, Hayes LG. 1996. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect. Immun. 64:2062-2069. (Pubitemid 26165667)
60. Wayne LG, Sohaskey CD. 2001. Nonreplicating persistence of Mycobacterium tuberculosis. Annu. Rev. Microbiol. 55:139-163. (Pubitemid 32978103)
61. WHO. 2011. Tuberculosis MDR-TB & XDR-TB 2011 progress report. WHO, Geneva, Switzerland.
62. Ziglam HM, Baldwin DR, Daniels I, Andrew JM, Finch RG. 2002. Rifampicin concentrations in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum following a single 600 mg oral dose in patients undergoing fibre-optic bronchoscopy. J. Antimicrob. Chemother. 50:1011-1015. (Pubitemid 36032825)